secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027549
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma Q2 net income $4.6M, product sales +175% YoY; full-year revenue guidance raised to ~$30M
--------------------------------------------------------------------------------

- Net income of $4.6M ($0.18 per share) vs net loss of $1.6M a year ago.
- Product sales and royalty revenue of $6.5M, up 175% YoY and 22% sequentially; 10th straight quarter of growth.
- Total Q2 revenue of $12.0M, including $5.5M from sale of neurology royalty interests.
- Raised full-year revenue guidance to approximately $30M; launched Betaine Anhydrous in May.
- ET-400 NDA submission on track for Q4 2023; cash $21.6M at quarter-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/0001493152-23-027549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer